Various research groups have explored nutritional, gastrointestinal, and immunologic factors in autism spectrum disorders (ASD), particularly during the late 1990s and early 2000s. Some of this work was presented at conferences sponsored by organizations such as the Autism Research Institute, including the Defeat Autism Now! (DAN!) meetings, which brought together clinicians and researchers investigating nonpharmacologic approaches.
Vitamin B6 and Magnesium
A number of small studies examined vitamin B6 used in combination with magnesium in individuals with autism. According to reviews cited by DAN!-affiliated researchers, multiple trials—including some double-blind, placebo-controlled studies—reported changes in behavior or symptoms when these nutrients were administered together. These studies were conducted across several countries and varied widely in design, outcome measures, and participant characteristics. The findings were not uniform, and the proposed mechanisms remained speculative.
Gluten-Free / Casein-Free Diets
Dietary interventions were also explored. A small study published in Nutritional Neuroscience (2002; 5(4):251–261) compared 10 children with autism placed on a gluten-free, casein-free diet with 10 autistic controls over one year. The investigators reported changes in behavioral measures in the dietary intervention group, while the control group did not show similar changes. Given the small sample size and non-blinded design, the findings were considered preliminary.
One hypothesis proposed at the time suggested that incomplete digestion of gluten and casein could lead to the formation of bioactive peptides with opioid-like properties. This hypothesis was debated in the literature and has not been conclusively established.
Gastrointestinal and Immune Findings
Other studies investigated immune and gastrointestinal features in subsets of individuals with autism. Research published in Molecular Psychiatry (2002; 7(4):375–382) examined children with regressive autism and reported immune-related cellular changes in intestinal tissue.
Neuroinflammatory markers were examined in postmortem and cerebrospinal fluid studies. Research published in Annals of Neurology (November 15, 2004) reported evidence of inflammatory changes in brain tissue samples from individuals with autism. Elevated cytokines and chemokines were also detected in cerebrospinal fluid samples from a small group of living children with autism, suggesting localized neuroimmune activity rather than systemic inflammation.
Context and Interpretation
Together, these studies reflect early exploratory research into possible nutritional, immune, and inflammatory features associated with autism. Many of the investigations were small, heterogeneous, and hypothesis-generating. While they contributed to discussion about potential biological subtypes within the autism spectrum, they did not establish standardized treatments or clinical protocols.
Subsequent research has continued to explore immune signaling, gut–brain interactions, and metabolic differences in autism using larger cohorts and more rigorous methodologies, with mixed and evolving results.
